Your AI-Trained Oncology Knowledge Connection!
A phase 2 study found that data from a 3-year follow up showed statistically significant improvements in overall survival for patients with high-risk locally advanced squamous cell carcinoma of the head and neck treated with an IAP antagonists with chemo-radiation therapy.
The Oncologic Drugs Advisory Committee voted in favor of the available data supporting the efficacy of remestemcel-L in pediatric patients with steroid-refractory acute graft-versus-host disease.
The implementation of optimized workup as a diagnostic workup in patients with head and neck cancer led to a significant reduction in the time-to-treatment interval.
Researchers found that breast cancer survivors who were prescribed adjuvant endocrine therapy and regularly performed moderate physical activity reported better health-related quality-of-life.
Study findings suggested that survivors with severe hearing loss are at a significantly increased risk for neurocognitive deficits, independent of what type of therapy they receive.
A study published in JCO Clinical Cancer Informatics found significant decreases nationwide in the number of patients being seen for cancer-related care due to the COVID-19 pandemic.
Researchers suggested that these findings support using minimal residual disease as a major stratification variable in all clinical trials to be conducted in patients with triple negative breast cancer.
These study results suggested that a longer time to surgery does not lower overall survival for women with early-stage breast cancer who had to delay operations due to the COVID-19 pandemic.
CancerNetwork® will be hosting a tweet chat on survivorship this Friday, August 14th, at 1 PM EST.
The American Society of Hematology released guidelines that “take providers through the conversations they have with newly diagnosed patients, almost in real-time.”
The expert oncologist/hematologist spoke with CancerNetwork® about the challenges brought to light by the current pandemic.
The study is evaluating itolizumab in patients with severe acute graft-versus-host disease as a first-line treatment concomitant with standard of care.
Bristol Myers Squibb announced that their phase 3 CheckMate-649 trial demonstrated superior overall survival and profession-free survival using nivolumab plus chemotherapy to treat patients with gastric and esophageal cancers.
Bristol Myers Squibb’s CheckMate-577 trial, which evaluated nivolumab to treat patients with resected esophageal or gastroesophageal junction cancer, met the primary end point of disease-free survival.
A complete response letter was issued to Fennec Pharmaceuticals regarding the new drug application for a unique formulation of sodium thiosulfate (Pedmark).
The GioTag study demonstrated that sequential afatinib and osimertinib improved overall survival among patients from the US with epidermal growth factor receptor mutation-positive non-small cell lung cancer and a T790M resistance mutation.
Data from the phase 3 CheckMate-743 trial showed a statistically significant overall survival benefit for patients with previously untreated, unresectable malignant pleural mesothelioma when treated with nivolumab plus ipilimumab.
The FDA approved Guardant360 CDx, the first liquid biopsy companion diagnostic that also uses next-generation sequencing technology to identify patients with any solid malignant neoplasm.
Researchers in Japan established optimized treatment modalities for patients with HPV-related oropharyngeal squamous cell carcinoma based on data from the Head and Neck Registry of Japan.
The oncologist from the Morrison Cancer Center explained why he believes the general population should not receive multi-gene panel testing.
Jennifer M. Yeh, PhD, spoke about study findings which indicated that instituting annual breast cancer screening with MRI at ages 25 to 30 years may reduce breast cancer mortality by 50% or more in survivors of childhood cancer.
The study evaluating atezolizumab in combination with paclitaxel compared to placebo plus paclitaxel did not meet its primary end point of progression-free survival in patients with metastatic triple-negative breast cancer.
The FDA cleared the clonoSEQ assay to detect and monitor minimal residual disease in blood or bone marrow from patients with chronic lymphocytic leukemia.
Data released from a phase 2b clinical trial showed statistically significant long-term survival for patients with stage III or IV melanoma at high-risk of recurrence.
Pfizer Inc.’s phase 3 CROWN trial examining lorlatinib to treat patients with ALK-positive NSCLC met its primary end point of improving progression-free survival when compared to crizotinib.
The FDA approved the first anti-BCMA therapy, belantamab mafodotin-blmf, to treat patients with relapsed/refractory multiple myeloma who have received 4 prior therapies.
The researcher from Quest Diagnostics spoke about a recent study which confirmed the benefit of using liquid-based cytology in cotesting for cervical cancer.
A recent study compared the risk of a second cancer diagnosis after primary cancer treatment following the use of either intensity-modulated radiotherapy, 3-dimensional conformal radiotherapy, or proton beam radiotherapy.
A study conducted by the Roswell Park Comprehensive Cancer Center found that patients undergoing radiation therapy for head and neck cancers were at a higher risk of less-favorable outcomes if they were unexpectedly hospitalized for dehydration, fever, or other ailments.
The MD Anderson Cancer Center expert discussed the future of acute myeloid leukemia treatment, and how the field is evolving rapidly.
